PMV Pharmaceuticals (PMVP) IPO Opens 94% Higher

Today's IPO for PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) opened for trading at $35 after pricing 11,765,000 shares of common stock at a public offering price of $18.00 per share.

In addition, PMV Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,764,750 shares of common stock at the initial public offering price less the underwriting discounts and commissions.

Goldman Sachs & Co. LLC, BofA Securities, Cowen and Evercore ISI are acting as joint book-running managers for the offering.

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey.

You May Also Be Interested In

• YPF Energía Eléctrica S.A. files for proposed NYSE IPO
• Jones Ventures INTL Acquisition1 prices $200M IPO on Nasdaq
• Research Alliance Corporation IV prices $75M IPO on Nasdaq